Stabilize movement reduce off periods
- Trial ID
- NCT06919822
- Official Title
- Somato-cognitive Action Network Targeted Epidural Modulation for Parkinson's Disease (STEM-PD): a Prospective Open-label Clinical Trial
- Goal
- Stabilize movement reduce off periods
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Changping Laboratory
- Study Type
- INTERVENTIONAL
- Enrollment
- 3 participants
- Conditions
- Parkinson Disease
- Interventions
- Personalized SCAN Targeted Epidural Modulation
Plain-Language Summary
Testing whether personalized epidural stimulation of the brain's somato-cognitive action network can stabilize movement and reduce the motor fluctuations and off periods that happen despite levodopa. The treatment surgically places epidural electrodes to deliver tailored electrical pulses that modulate abnormal brain circuits involved in movement, so it is an implant-based neuromodulation designed to work alongside levodopa rather than change how the drug is processed. The study seeks people aged 40 to 75 who have had Parkinson's for at least 5 years, are Hoehn-Yahr stage 2 to 4, respond to levodopa (≥30% improvement) but still have motor fluctuations, and it excludes those with other implants like DBS, epilepsy, severe medical or psychiatric issues, or MRI contraindications.
Locations
- The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Personalized SCAN Targeted Epidural Modulation. Testing whether personalized epidural stimulation of the brain's somato-cognitive action network can stabilize movement and reduce the motor fluctuations and off periods that happen despite levodopa. The treatment surgically places epidural electrodes to deliver tailored electrical pulses that modulate abnormal brain circuits involved in movement, so it is an implant-based neuromodulation designed to work alongside levodopa rather than change how the drug is processed. The study seeks people aged 40 to 75 who have had Parkinson's for at least 5 years, are Hoehn-Yahr stage 2 to 4, respond to levodopa (≥30% improvement) but still have motor fluctuations, and it excludes those with other implants like DBS, epilepsy, severe medical or psychiatric issues, or MRI contraindications.
- Who can participate?
- Participants must be between 40 Years and 75 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 9 months.